While there are no studies recorded on the use of IL-6 inhibitors in treating CME from retinal vascular conditions, such as diabetic retinopathy or RVO, IL-6 inhibitors may provide another treatment option due the role of IL-6 in vascular inflammation and disruption of the blood–retina barrier. This evidence concerns the gene IL6 and diabetic retinopathy.